OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
Carl Graham, Thomas Lechmere, Aisha Rehman, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010882-e1010882
Open Access | Times Cited: 13
Carl Graham, Thomas Lechmere, Aisha Rehman, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010882-e1010882
Open Access | Times Cited: 13
Showing 13 citing articles:
Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 19
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 19
Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment
Jim Keijser, Eileen W Stalman, Luuk Wieske, et al.
EBioMedicine (2025) Vol. 113, pp. 105620-105620
Closed Access
Jim Keijser, Eileen W Stalman, Luuk Wieske, et al.
EBioMedicine (2025) Vol. 113, pp. 105620-105620
Closed Access
SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy
Peter K. Cheung, Hope R. Lapointe, Yurou Sang, et al.
AIDS (2023) Vol. 37, Iss. 5, pp. F11-F18
Open Access | Times Cited: 11
Peter K. Cheung, Hope R. Lapointe, Yurou Sang, et al.
AIDS (2023) Vol. 37, Iss. 5, pp. F11-F18
Open Access | Times Cited: 11
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection
Keon Young Lee, Kyoung‐Ho Song, Kyoung Hwa Lee, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3953-3960
Closed Access | Times Cited: 2
Keon Young Lee, Kyoung‐Ho Song, Kyoung Hwa Lee, et al.
Vaccine (2024) Vol. 42, Iss. 19, pp. 3953-3960
Closed Access | Times Cited: 2
Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 7
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
mBio (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 7
Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting
Jeffrey Seow, George Jefferson, Michael R. Keegan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Jeffrey Seow, George Jefferson, Michael R. Keegan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
George N. Llewellyn, Hsu-Yu Chen, Geoffrey L. Rogers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Wen Shi Lee, Hyon‐Xhi Tan, Arnold Reynaldi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
Eileen W Stalman, Luuk Wieske, Jim Keijser, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 3, pp. 754-766.e7
Open Access
Eileen W Stalman, Luuk Wieske, Jim Keijser, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 3, pp. 754-766.e7
Open Access
Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting
Jeffrey Seow, George Jefferson, Michael D. Keegan, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 11, pp. e1012724-e1012724
Open Access
Jeffrey Seow, George Jefferson, Michael D. Keegan, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 11, pp. e1012724-e1012724
Open Access
Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Jeffrey Seow, Zayed A. Shalim, Carl Graham, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
SARS-CoV-2 vaccination strategies: Should the extended dosing interval strategy be implemented in future pandemics?
Sandra Valderrama, Juliana Cuervo-Rojas, Samuel Martínez-Vernaza, et al.
Travel Medicine and Infectious Disease (2023) Vol. 56, pp. 102650-102650
Open Access | Times Cited: 1
Sandra Valderrama, Juliana Cuervo-Rojas, Samuel Martínez-Vernaza, et al.
Travel Medicine and Infectious Disease (2023) Vol. 56, pp. 102650-102650
Open Access | Times Cited: 1
Longitudinal Dynamics of the SARS-CoV-2 Antibody Repertoire after SARS-CoV-2 Delta and Omicron Breakthrough Infections in Patients with Immune-Mediated Inflammatory Diseases
Eileen W Stalman, Luuk Wieske, Jim Keijser, et al.
(2023)
Closed Access
Eileen W Stalman, Luuk Wieske, Jim Keijser, et al.
(2023)
Closed Access
